Advertisement
New Zealand markets closed
  • NZX 50

    12,105.29
    +94.63 (+0.79%)
     
  • NZD/USD

    0.5974
    -0.0031 (-0.52%)
     
  • NZD/EUR

    0.5535
    -0.0008 (-0.14%)
     
  • ALL ORDS

    8,153.70
    +80.10 (+0.99%)
     
  • ASX 200

    7,896.90
    +77.30 (+0.99%)
     
  • OIL

    83.06
    +1.71 (+2.10%)
     
  • GOLD

    2,240.70
    +28.00 (+1.27%)
     
  • NASDAQ

    18,254.69
    -26.15 (-0.14%)
     
  • FTSE

    7,952.62
    +20.64 (+0.26%)
     
  • Dow Jones

    39,807.37
    +47.29 (+0.12%)
     
  • DAX

    18,492.49
    +15.40 (+0.08%)
     
  • Hang Seng

    16,541.42
    +148.58 (+0.91%)
     
  • NIKKEI 225

    40,168.07
    -594.66 (-1.46%)
     
  • NZD/JPY

    90.3760
    -0.4040 (-0.45%)
     

Regeneron (REGN) Outpaces Stock Market Gains: What You Should Know

Regeneron (REGN) closed at $562.71 in the latest trading session, marking a +1.92% move from the prior day. This change outpaced the S&P 500's 0.37% gain on the day.

Coming into today, shares of the biopharmaceutical company had lost 14.66% in the past month. In that same time, the Medical sector lost 4.25%, while the S&P 500 gained 2.13%.

REGN will be looking to display strength as it nears its next earnings release, which is expected to be November 4, 2021. In that report, analysts expect REGN to post earnings of $9.54 per share. This would mark year-over-year growth of 14.11%. Meanwhile, our latest consensus estimate is calling for revenue of $2.6 billion, up 13.53% from the prior-year quarter.

Looking at the full year, our Zacks Consensus Estimates suggest analysts are expecting earnings of $62.36 per share and revenue of $13.93 billion. These totals would mark changes of +98.16% and +63.92%, respectively, from last year.

ADVERTISEMENT

Any recent changes to analyst estimates for REGN should also be noted by investors. These revisions typically reflect the latest short-term business trends, which can change frequently. As a result, we can interpret positive estimate revisions as a good sign for the company's business outlook.

Research indicates that these estimate revisions are directly correlated with near-term share price momentum. We developed the Zacks Rank to capitalize on this phenomenon. Our system takes these estimate changes into account and delivers a clear, actionable rating model.

Ranging from #1 (Strong Buy) to #5 (Strong Sell), the Zacks Rank system has a proven, outside-audited track record of outperformance, with #1 stocks returning an average of +25% annually since 1988. Over the past month, the Zacks Consensus EPS estimate has moved 2.34% higher. REGN is currently sporting a Zacks Rank of #1 (Strong Buy).

Looking at its valuation, REGN is holding a Forward P/E ratio of 8.85. For comparison, its industry has an average Forward P/E of 24.64, which means REGN is trading at a discount to the group.

It is also worth noting that REGN currently has a PEG ratio of 1.04. The PEG ratio is similar to the widely-used P/E ratio, but this metric also takes the company's expected earnings growth rate into account. The Medical - Biomedical and Genetics industry currently had an average PEG ratio of 1.53 as of yesterday's close.

The Medical - Biomedical and Genetics industry is part of the Medical sector. This group has a Zacks Industry Rank of 179, putting it in the bottom 30% of all 250+ industries.

The Zacks Industry Rank gauges the strength of our industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.

You can find more information on all of these metrics, and much more, on Zacks.com.


Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
 
Regeneron Pharmaceuticals, Inc. (REGN) : Free Stock Analysis Report
 
To read this article on Zacks.com click here.